Dr. Wright is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12631 E 17th Ave
Aurora, CO 80045Phone+1 303-724-1784
Summary
- I am a fourth year medical student at UCSF School of Medicine. My interests include internal medicine, immunology, oncology, and health equity.
Education & Training
- University of ColoradoResidency, Internal Medicine, 2022 - 2025
- University of California San Francisco School of MedicineClass of 2022
Publications & Presentations
PubMed
- 5 citationsEvaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.Jordyn Silverstein, Francis Wright, Michelle Wang, Arabella Young, Daniel Kim
The Oncologist. 2023-10-03 - 29 citationsConstrained chromatin accessibility in PU.1-mutated agammaglobulinemia patientsCarole Le Coz, David N. Nguyen, Chun Su, Brian Nolan, Amanda V. Albrecht
The Journal of Experimental Medicine. 2021-07-05 - 13 citationsDifferential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.Daniel Kwon, Jonathan Chou, Steven Yip, Melissa A. Reimers, Li Zhang
Cancer. 2021-06-15
Journal Articles
- Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patientsCarole Le Coz, David N Nguyen, Chun Su, Brian E Nolan, Amanda V Albrecht, Suela Xhani, Di Sun, Benjamin Demaree, Piyush Pillarisetti, Caroline Khanna, Francis Wright, ..., Journal of Experimental Medicine, 7/5/2021
- Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerKwon, D.H., Chou, J., Yip, S.M., Reimers, M.A., Zhang, L., Wright, F., Dhawan, M.S., Borno, H.T., Desai, A., Aggarwal, R.R., Wyatt, A.W., Small, E.J., Alva, A.S., Chi,..., Cancer, 6/15/2021
- TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorKouchkovsky, I., Zhang, L., Philip, E.J., Wright, F., Kim, D.M., Natesan, D., Kwon, D., Ho, H., Ho, S., Chan, E., Porten, S.P., Wong, A.C., Desai, A., Huang, F.W., Cho..., Journal for Immunotherapy of Cancer, 5/9/2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: